NBIX
Neurocrine Biosciences, Inc.
Stock
$143.18+2.47 (+1.76%)Close Oct 2, 2026
- EBITDA, 2025
- $645M
- YoY, 2025
- +8.6%
- 5-year CAGR
- +30.3%
EBITDA
EBITDA by fiscal year
| Period | EBITDA | YoY |
|---|---|---|
| 2025 | $645M | +8.6% |
| 2024 | $594M | +121.1% |
| 2023 | $269M | +1.7% |
| 2022 | $264M | +132.9% |
| 2021 | $113M | −33.9% |
| 2020 | $172M | +115.3% |
| 2019 | $80M | +95.2% |
| 2018 | $41M | — |
| 2017 | −$129M | — |
| 2016 | −$146M | — |
| 2015 | −$93M | — |
| 2014 | −$64M | — |
| 2013 | −$49M | — |
| 2012 | $2.1M | −93.9% |
| 2011 | $35M | — |
| 2010 | −$12M | — |
| 2009 | −$50M | — |